• Legal
  • Ethical
  • General information
  • Links
  • Medical professionals
  • Researchers
  • Industry
  • Patients
  • Regulatory bodies
  • General public
  • Use an ACGT resource
  • Add my resource to ACGT
  • News list
  • Events
  • Newsletters
  • RSS feed
  • Public Deliverables
  • Dissemination materials
  • Publications
Member area
Print this page
You are here:HomeACGT for youRegulatory bodiesClinical TrialsGeneral information
banner
menu separation
  • regulatory bodies
  • Legal and ethical
  • Research
  • Clinical Trials
  • Software services
  • Simulators
menu separation
  • Main menu
  • ACGT for you
  • General Information
  • User information
  • News
  • Consortium
  • Documents
  • Join us
  • Contact
  • FAQ
  •  

 

ACGT Newsletter

View Summer 2010 Issue

If you want to subscribe to the ACGT newsletter, please send us an email.

  • medical professionals
  • researchers
  • industry
  • patients
  • regulatory bodies
  • general public

Clinical Trials

General Information

This page includes scientific papers, results and related data that are published by ACGT researchers in connection with the Breast Cancer and Wilm's Tumour clinical trials. Information is structured by Clinical Trial.

Breast Cancer Trials

For more information you may contact:

For the Breast Cancer trials at Jules Bordet:

Dr. Christine Desmedt: christine.desmedt@bordet.be

Wilm's Tumour Trials

Wilm's tumour is the most common malignant renal tumour in children. Dramatic improvements in survival have occurred as the result of advances in anesthetic and surgical management, irradiation and chemotherapy. Today treatments are based on several multicentre trials and studies conducted by the SIOP in Europe and COG in the USA. Main objectives of these trials and studies are to treat patients according to well-defined risk groups in order to achieve highest cure rates, to decrease the frequency and intensity of acute and late toxicity and to minimize the cost of therapy. In that way the SIOP trials and studies largely focus on the issue of preoperative therapy. The concept of neoadjuvant chemotherapy plays an important role in the treatment for most pediatric solid tumours today. The complete surgical removal of a shrunken tumour is facilitated, mutilation caused by surgical procedures is minimized or avoided and micrometastases, not visible at diagnosis, are treated as early as possible. Besides that, response to treatment can be measured individually by tumour volume reduction and/or percentage of therapy induced necrosis at the time of surgery in the histological specimen. This might give an early individual prognostic parameter and can be used for further stratifying and more individualizing postoperative treatment as in other pediatric cancers. Clinical trials for Wilm's tumour continue to seek risk factors for further stratifying and individualizing treatment. Questions in the future will mainly address molecular genetic findings for a better understanding of Wilm's tumour, hopefully influencing treatment and outcome.

Links:

CureSearch www.curesearch.org

Kinderkrebsinfo www.kinderkrebsinfo.de/index_eng.html

Wilm's Tumour www.curesearch.org/for%5Fpatients/newlydiagnosed/

www.nephroblastom.de

 

For more information you may contact:

Prof. Dr. Norbert Graf: Norbert.Graf@uniklinikum-saarland.de

 

Design: HealthGrid
  • home
  • site map
  • disclaimer
  • contact